Realising the Potential of AI in Life Sciences
We turn complex biological, clinical, and medical data into competitive advantage. Expert-led AI strategy and engineering for a regulated world.
Innovation Without Compromise
In Life Sciences, Artificial Intelligence is not just about efficiency; it is about unlocking the value hidden in decades of research and accelerating patient outcomes. However, the path to adoption is complicated by messy, unstructured historical data, strict UK and EU regulatory frameworks, and the absolute necessity of clinical safety.
Attercop does not offer generic solutions. We partner with a wide variety of Life Sciences firms including CDOs, MedComms, MedTech and Health providers to build AI capabilities that are pragmatic, scalable, and compliant. We understand that your data is your most valuable asset, and we know how to engineer the systems required to leverage it safely.
Tailored Services for Life Sciences
Examples of our specialist AI capabilities designed for the unique challenges of Life Sciences firms.
Advanced RAG Systems
Knowledge Engineering & Hybrid Retrieval
Transform decades of unstructured research data into interconnected, queryable knowledge. Combine Knowledge Graphs, tabular models, and semantic search to create systems that let you "talk" to your data.
Strategic Planning
AI Strategy & Roadmaps
Move beyond ad-hoc experiments to cohesive company-wide AI capability. From automating medical writing to accelerating drug formulation – with the governance structures required to operate safely.
UK/EU Regulatory Focus
Governance, Risk & Compliance
Balance the disruptive power of Generative AI with rigorous risk management. Your algorithms and data practices meet the high standards expected in regulated healthcare markets.
Intelligent Process Automation
Agentic Automation
Streamline repetitive, time-bound workflows. FOI response drafting, resource planning, communication automation, and conversational AI integration for customer service.
M&A Technical Assessment
AI & Data Tech Due Diligence
Deep technical assessment for investors evaluating Bioinformatics platforms, Pharma service providers, or MedTech innovators. Ensure the technology is scientifically valid and technically sound.
Proven Results
Real transformations for Life Sciences organisations across pharma, MedTech, and medical communications.
Developing a Strategic AI Roadmap
How we helped a global medical communications leader move from ad-hoc initiatives to a comprehensive AI strategy, embedding AI across medical, commercial, and market access functions.
Unlocking Historical Research Data
Designing a solution for a leading CRDO to transform unstructured historical reports into an explorable Knowledge Graph, streamlining research and insight generation.
AI Enablement for Neurodiversity
Partnering with a science-backed platform to design multimodal AI systems and provide strategic guidance on knowledge graph implementation for content customisation.
Commercial Integration of a Strategic AI Acquisition
Assisting a pharma technology partner in bridging the gap between an acquired scientific team and commercial objectives, accelerating value generation.
Trusted by Life Sciences Leaders
Why Attercop?
We are not just consultants; we are industry veterans who have sat in your seat. Our leadership team combines deep technical heritage with executive accountability in regulated sectors, ensuring we bridge the gap between scientific ambition and commercial reality.
Our team's background includes:
- •Pharma Leadership: Experience as the Chief Technology Officer of a leading Pharma data business, driving digital transformation and data strategy.
- •Medical Device Innovation: First-hand experience leading a deep-tech venture from R&D concept through to the successful registration of a Class IIa medical device.
- •Healthcare Operations: Executive leadership as the Chief Technology & Transformation Officer for a major national healthcare charity.
- •Strategic Oversight: Experience serving as Board Observers for MedTech innovators, providing the commercial scrutiny required to scale in this sector.